BillionToOne Enhances Leadership to Propel Growth Strategies
New Leaders Bring Deep Expertise in Operational Efficiency
BillionToOne, Inc., a pioneering molecular diagnostics company focused on providing innovative and accessible testing solutions, has unveiled significant additions to its executive team. These appointments aim to bolster the growth of its advanced UNITY and Northstar diagnostic platforms, enhancing operational efficiency and strategic execution.
Dr. Oguzhan Atay, co-founder and CEO of BillionToOne, expressed his enthusiasm about the new leaders joining the firm. "We’re thrilled to welcome such talented leaders to BillionToOne. Both Jean and John bring a unique skill set and extensive experience that will be instrumental as we scale our operations and establish ourselves as a generational company," he stated.
Jean Hayden joins BillionToOne as the Vice President of Business Operations and Chief of Staff. With over two decades of expertise, she has effectively translated strategy into execution within high-growth environments. Previously, she held leadership roles in various organizations, including BCG, where she drove transformations for large healthcare companies, and Google Cloud, where she orchestrated improvements in customer experience, leading to significant revenue growth. Her recent tenure as VP of Revenue Strategy and Operations at Databricks gave her further insights into operational scaling. At BillionToOne, she will oversee and optimize business operations to ensure sustained hypergrowth.
In addition, John Lister has been appointed Chief Administrative Officer. His previous roles include prominent positions at Dexcom, a leader in continuous glucose monitoring. At Dexcom, he was crucial in expanding the company from merely 70 employees to a workforce of over 6,000, while guiding revenue growth from zero to more than $1.5 billion. He also served as COO for Tidepool, specializing in diabetes software solutions. In his new role, Lister will lead various teams, including People, Legal, IT, and Quality Assurance/Regulatory Affairs, driving efficiencies across the organization.
BillionToOne's UNITY Complete® platform revolutionizes prenatal testing. It is the only clinically validated, non-invasive test that delivers a comprehensive fetal risk assessment from a single maternal blood sample. This innovative approach leverages fetal cell-free DNA to enable early detection and personalized care, promoting healthier pregnancy outcomes.
The company’s oncology offerings, Northstar Select® and Northstar Response®, stand at the forefront of liquid biopsy technology. Northstar Select is particularly noteworthy for its precision as a therapy selection assay for late-stage cancers, significantly outperforming competitors in terms of sensitivity. Meanwhile, Northstar Response provides unparalleled precision for monitoring tumor dynamics across various cancer types, making it an invaluable tool for clinicians managing advanced cancer treatment.
To explore further about BillionToOne and its cutting-edge advancements in molecular diagnostics, potential clients and interested parties can visit their official website.
About BillionToOne
BillionToOne is dedicated to making molecular diagnostics more powerful and accessible. The company’s unique Quantitative Counting Templates™ (QCT™) platform allows for precise DNA molecule counting at the single-molecule level, setting them apart in the industry.
Media Contact: [media-contact]
Frequently Asked Questions
What is BillionToOne's primary focus?
BillionToOne specializes in developing advanced molecular diagnostic tests that are accessible and efficient.
Who are the recent executive appointments at BillionToOne?
The new appointees are Jean Hayden as Vice President of Business Operations and Chief of Staff, and John Lister as Chief Administrative Officer.
What is the UNITY Complete® platform?
UNITY Complete® is a clinically validated non-invasive prenatal test that assesses fetal risks from a single maternal blood sample.
How does Northstar Select® contribute to cancer care?
Northstar Select® enhances cancer therapy selection through unparalleled sensitivity and precision for late-stage cancers.
What is BillionToOne's mission?
The mission is to empower molecular diagnostics, making them more powerful and efficient for wider accessibility in healthcare.
